LIVN Stock Overview
A medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LIVN from our risk checks.
LivaNova PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$61.07 |
52 Week High | US$64.48 |
52 Week Low | US$42.75 |
Beta | 0.93 |
1 Month Change | -4.80% |
3 Month Change | 16.59% |
1 Year Change | 31.79% |
3 Year Change | -23.75% |
5 Year Change | -18.41% |
Change since IPO | 408.92% |
Recent News & Updates
Recent updates
LivaNova: Focus Is Paying Off
May 12These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong
Apr 08Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?
Feb 05A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)
Jan 15LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry
Dec 25LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company
Nov 29We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Nov 08At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?
Oct 16Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?
Sep 25Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Jul 26Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?
Jul 03An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued
Jun 09Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital
Apr 13What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?
Mar 13Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Feb 15Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up
Nov 25Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Oct 29LivaNova Loses Profit Momentum On Higher R&D Expense
Oct 13LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate
Oct 11FDA labels recall of blood bypass pump systems by LivaNova as most serious
Sep 30Returns On Capital At LivaNova (NASDAQ:LIVN) Have Hit The Brakes
Aug 09LivaNova PLC Non-GAAP EPS of $0.53 beats by $0.01, revenue of $254.2M beats by $4.65M, lowers FY earning guidance
Aug 03Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?
Jul 19A Look At The Fair Value Of LivaNova PLC (NASDAQ:LIVN)
Jun 27LivaNova Matures Into Profitability, Still Waiting On DTD
May 10Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal
Apr 05LivaNova Continues To Be A Spring-Loaded Opportunity In Neuromodulation
Feb 11Is LivaNova PLC (NASDAQ:LIVN) Trading At A 35% Discount?
Jan 30Shareholder Returns
LIVN | US Medical Equipment | US Market | |
---|---|---|---|
7D | 2.5% | -0.8% | -0.6% |
1Y | 31.8% | 1.9% | 22.5% |
Return vs Industry: LIVN exceeded the US Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: LIVN exceeded the US Market which returned 22.5% over the past year.
Price Volatility
LIVN volatility | |
---|---|
LIVN Average Weekly Movement | 6.1% |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LIVN has not had significant price volatility in the past 3 months.
Volatility Over Time: LIVN's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 2,900 | Vladimir Makatsaria | www.livanova.com |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
LivaNova PLC Fundamentals Summary
LIVN fundamental statistics | |
---|---|
Market cap | US$3.31b |
Earnings (TTM) | -US$31.77m |
Revenue (TTM) | US$1.19b |
2.8x
P/S Ratio-104.1x
P/E RatioIs LIVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LIVN income statement (TTM) | |
---|---|
Revenue | US$1.19b |
Cost of Revenue | US$376.68m |
Gross Profit | US$808.36m |
Other Expenses | US$840.12m |
Earnings | -US$31.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.59 |
Gross Margin | 68.21% |
Net Profit Margin | -2.68% |
Debt/Equity Ratio | 51.1% |
How did LIVN perform over the long term?
See historical performance and comparison